|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry显示文摘瞄准:为颜色检测新浆液简历标记由浆液蛋白质与提高表面的激光解吸附作用 ionisation 介绍的表面的癌症(CRC )-- 飞行团分光术(SELDI-TOF MS ) 的时间。方法:二个独立浆液样品集合与 ProteinChip 技术独立被分析(集合 A:40 CRC+49 健康控制;集合 B:37 CRC+31 健康控制) ,有一个弱阳离子的使用的芯片交换一半和缓冲区 pH 5。差别的歧视的力量表示了蛋白质与一个分类树算法被估计。产生分类树的敏感和特性被盲目地从集合 B 并且反过来也如此从集合 A 把数据用于产生的树获得。CRC 浆液蛋白质侧面也与从胸的那些相比,卵巢,前列腺,和非小的房间肺癌症。结果:Mass-to-charge 比率(m/z ) 3.1x10 (3 ) , 3.3x10 (3 ) , 4.5x10 (3 ) , 6.6x10 (3 ) 和 28x10 (3 ) 在最好执行的分类树上被用作分类器。树敏感和特性在 65% 和 90% 之间。大多数这些歧视的 m/z 价值在调查的另外的瘤类型也是不同的。M/z 3.3x10 (3 ) ,在大多数树上的主要分类器,是 6.6x10 (3 ) 的一种二倍地控告的形式 -Da 蛋白质。后者作为 apolipoprotein C-I 被识别。M/z 3.1x10 (3 ) 作为 apolipoprotein A-I 作为白朊,和 m/z 28x10 (3 ) 的 N 终端碎片被识别。结论:分类树模式分析跟随的 SELDI-TOF MS 是为为 CRC 发现新浆液标记的一种合适的技术。Biomarkers 能与高敏感和特性在独立样品集合被识别并且 reproducibly 检测了。尽管为 CRC 不特定,这些简历标记在监视的疾病和治疗有一个潜在的角色。 | Judith YMN Engwegen Helgi H Helgason Annemieke Cats Nathan Harris Johannes MG Bonfrer Jan HM Schellens Jos H Beijnen | 2006 | World Journal of Gastroenterology2006，12，10： | 45 |
| 2 | Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma显示文摘 | Korse CM Bonfrer JM | 2003 | Melanoma Res2003，13，1： | 1 |
| 3 | Application of tumour markers in clinical practice 显示文摘 | Keuren JF Thomas CM Bonfrer JM | 2009 | Ned Tijdschr Geneeskd2009，153，： | 1 |
| 4 | Value of Cyfra21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer 显示文摘 | Gaarenstroom KN Bonfrer JMG Korse CM | 1997 | Anticancer Res1997，17，48： | 1 |
| 5 | Can initial serum cyfra-21-1,SCC antigen,and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis显示文摘 | Gaarenstroom K N Kenter G G Bonfrer J M | | 0，，01： | 1 |
| 6 | Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma 显示文摘 | HAMBERG A P KORSE C M BONFRER J M | 2003 | Melanoma Res2003，13，1： | 1 |
| 7 | Can initial serum cyfra-21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis显示文摘 | Gaarenstroom K N Kenter G G Bonfrer J M | 2000 | Gynecol Oncol2000，77，1： | 1 |
| 8 | CA125 in ovarian can cer : Europe - an Group on Tumor Markers guidelines for clinical use显示文摘 | Duly MJ Bonfrer JM Kulpa J | 2005 | Int J Gynecol Cancer2005，15，5： | 1 |
| 9 | Highly elevated serum CA125 levels in a patient with cardiac failure显示文摘 | Hopman EH Helmerhorst TJ Bonfrer JM | 1993 | Eur J Ob- stet Gvnecol Reprod Bio11993，48，： | 1 |
| 10 | lmnmnophenotypic markers to differentiate between benign and malignant melanocytic lesions显示文摘 | Keijser S Missotten GS Bonfrer JM | 2006 | Ophthalmol2006，90，： | 1 |
| 11 | CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use显示文摘 | Duffy MJ Bonfrer JM Kulpa J | 2005 | Int J Gynecol Cancer2005，15，5： | 1 |
| 12 | Investigating the effects of store-brand introduction on retailer demand and pricing behavior显示文摘 | Chintagunta P K Bonfrer A Song I | 2002 | Management Science2002，48，10： | 1 |
| 13 | Can initial serum cyfra 21-1,SCC antigen,and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis显示文摘 | Gaanenstroom KN Kenter GG Bonfrer JM | 2000 | Gynecol Oncol2000，77，1： | 1 |
| 14 | SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity显示文摘 | Gast M C Bonfrer J M van Dulken E J | 2006 | Cancer Biomark2006，2，6： | 1 |
| 15 | CA125 in ovarian cancer: European Group on tumor makers guidelines for clinical use显示文摘 | Duffy MJ Bonfrer JM Kulpa J | 2005 | Int J Gynecol Cancer2005，15，5： | 1 |
| 16 | Serum neuron-specific enolase and lactate dehydrogeoase as predictors of response to chemotherapy and survival in non-small cell lung cancer显示文摘 | Zandwijk N Jassem E Bonfrer JM | 1992 | Semin Oncol1992，19，1： | 1 |
| 17 | Can initial serum cyfra 21-1,SCC antigen,and TPA levels in squamous cell cervical cancer predict lymph node metastasis or prognosis?显示文摘 | Gaarenstroom KN Kenter GG Bonfrer JM | 2000 | Gynecol Oncol2000，77，1： | 1 |
| 18 | Tumour markers in gynaecological cancers-EGTM recommendations显示文摘 | Bonfrer JMG Duffy MJ Radtke M | 1999 | Anticancer Res1999，19，： | 1 |
| 19 | Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy显示文摘 | S. Ruth MD A. A. M. Hart MSc J. M. G. Bonfrer MD V. J. Verwaal MD F. A. N. Zoetmulder MD PhD | 2002 | Annals of Surgical Oncology2002，，10： | 1 |
| 20 | CA125in ovarian cancer:European Group on Tumor Markers guidelines for clinical use显示文摘 | Duffy MJ Bonfrer JM Kulpa J | 2005 | Int J Gynecol Canc-er2005，15，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员